Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Chapter 7

Infections and multiple sclerosis

ARUN VENKATESAN AND RICHARD T. JOHNSON*

Department of Neurology, Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, MD, USA

INTRODUCTION

Infectious causes of multiple sclerosis have been proposed for over 100 years. During the past half-century three areas of investigation have given greater credence to the role of infectious agents, particularly viruses, in the initiation and/or exacerbations of multiple sclerosis: (1) epidemiologic studies indicate that multiple sclerosis is related, in part, to environmental exposure followed by a long latency period, and exacerbations of disease often follow virus-like illnesses; (2) studies in animal and other human demyelinating diseases have demonstrated a variety of mechanisms by which infectious agents can have long incubation periods, induce relapsing and remitting disease, and cause myelin destruction with relative preservation of axons; and (3) studies in patents with multiple sclerosis have consistently shown enhanced immune responses, particularly to viral antigens.

Genetic, autoimmune, or infectious causation had partisan advocates in the past, but a multifactorial etiology is now generally accepted. Genetic factors are clearly important in multiple sclerosis, but monozygotic twins have only a 14–30% concordance, suggesting a major role for environmental factors. Assuming the pathogenesis of lesions is immunologically driven, what evokes the response remains unknown. Infections remain plausible explanations for the initiation of these responses and for the clinical and pathological features of the disease.

Since the earlier edition of this chapter in the Handbook of Clinical Neurology over 25 years ago (Johnson, 1985), hundreds of additional papers have been published on infectious agents in multiple sclerosis. Nevertheless, the arguments for or against a virus or bacteria in the cause of multiple sclerosis seems not one whit stronger or weaker than it was more than two decades ago. A shift has occurred, however, both in methodology and goals. New methods of detection, localization, and quantitation of infectious agents are now available, and the focus of studies has shifted to known agents rather than the search for a unique “multiple sclerosis virus.”

EARLY OBSERVATIONS IMPLICATING INFECTIONS

Jean Martin Charcot described the clinical and pathologic features of multiple sclerosis in a series of lectures in 1868 (Murray, 2005). Since theories of humors causing diseases were still in vogue, he proposed that exposure to cold, physical injury, or emotional stress might bring on the disease. Over the subsequent 15 years, the work of Koch and Pasteur established microbial causes for many diseases. Thus, in historical perspective it is predictable that in 1884 Charcot’s student and successor, Pierre Marie, proposed infections as the cause for multiple sclerosis (Marie, 1884). Indeed, in the afterglow of Pasteur’s widely hailed discovery of postexposure immunization against rabies virus, Marie prematurely predicted a vaccine would soon be available for multiple sclerosis.

In the first half of the 20th century, reports of spirochetes began with the study of Kuhn and Steiner (1917), who claimed to have recovered them from the spinal fluid of patients with multiple sclerosis by the inoculation of guinea pigs and rabbits. Subsequently, Steiner (1952) reported similar organisms by direct staining of brains and spinal cords of patients. He named the putative agent Spirochaeta myelophthora. In 1957 another laboratory reported the cultivation of spirochetes from spinal fluids from patients with multiple sclerosis (Ichelson, 1957). This claim was confirmed and denied in subsequent reports but was finally

*Correspondence to: Richard T. Johnson, MD, Department of Neurology, Johns Hopkins Hospital, Pathology 627, Baltimore, MD 21287, USA. Tel: +1-410-614-5835, Fax: +1-410-502-7609, E-mail: rtj@jhmi.edu
settled by an extensive negative study using Ichelson’s methods, except for the use of autoclaved water (Kurtzke et al., 1962).

In the 1930s a putative virus (possibly a Mycoplasma) was reported to have been isolated from the spinal fluids of 176 of 189 patients with multiple sclerosis (Chevassut, 1930). This organism was named *Spherula insularis*, a vaccine was produced against the agent, and over 100 patients were treated. Enthusiasm ended when an oddly uninformative retraction was published by the clinician involved in the studies (Purves-Stewart, 1930, 1931; Murray, 2005). On the basis of serologic tests Le Gac (1960) proposed a *Rickettsia* in multiple sclerosis. Even protozoa were implicated, with the reported recovery of *Toxoplasma gondii* from the spinal fluid and blood of patients (Bequignon, 1956). In addition, there were a number of reports of the transmission of neurologic disease to a variety of animals inoculated with the tissues and spinal fluid of patients with multiple sclerosis (Innes and Kurland, 1952). None withstood scrutiny or independent confirmation.

An important early advance in the understanding of immune responses in demyelinating diseases came from experimental virology. Following measles and vaccinia virus infections, an acute encephalomyelitis occasionally develops that is characterized by perivenular demyelination of the brain and spinal cord. The neuroparalytic complications of rabies virus vaccines prepared in neural tissues bore a striking histopathologic resemblance to these virus-induced diseases. Thomas Rivers, the father of American virology, was intrigued by this similarity, and in the course of his studies with vaccinia virus, he inoculated monkeys with homogenates of normal neural tissue. After 6 months of repeated injections, several monkeys developed inflammatory demyelinating encephalitis simulating postinfectious encephalomyelitis and the neuroparalytic complications of rabies vaccines (Rivers and Schwentker, 1935). This was the first induction of experimental allergic encephalomyelitis. The subsequent claim by Schaltenbrand (1943) of transmission of multiple sclerosis to monkeys presumably represented an independent finding of this phenomenon, since the inflammation and demyelination that he induced in monkeys followed repeated injections of human neural tissue.

Experimental allergic (autoimmune) encephalomyelitis became a practical disease model after 1947, when Kabat and colleagues found that the experimental disease could be reliably reproduced in some species by a single injection of brain tissue if emulsified in Freund’s complete adjuvant. The antigens proved to be specific amino acid sequences of myelin proteins, the immunopathologic response was found to be cell-mediated, and the disease could be passively transferred with sensitized lymphocytes. Experimental autoimmune encephalomyelitis became the prototype experimental autoimmune disease, and it simulates acute disseminated encephalomyelitis in humans (Johnson et al., 1984; Johnson, 1998). Since the 1950s it has also been presented as an experimental model of multiple sclerosis, but this analogy seems overdrawn (Subramaniam and Steiner, 2005).

After mid-century the landscape changed with renewed interest in viruses as causes of chronic neurologic diseases. Between 1967 and 1971 the transmission of kuru and Creutzfeldt–Jakob disease and the recovery of viruses from subacute sclerosing panencephalitis and progressive multifocal leukoencephalopathy led to widespread anticipation that multiple sclerosis would soon be transmitted or prove to yield consistent viral recovery (Johnson, 1998). The epidemiologic studies have continued to suggest an environmental factor, studies in animals and humans delineated more mechanisms by which viruses can lead to acute and chronic demyelinating diseases, and new methodologies have incriminated different groups of agents that may play a role in the pathogenesis of multiple sclerosis. The optimism of the 1970s, however, has waned.

**EPIDEMIOLOGIC STUDIES IMPLICATING INFECTION**

**Geographic distribution**

National and regional death rates and over 300 prevalence studies show an uneven geographic distribution of multiple sclerosis (Kurtzke, 2005). The prevalence of over 200 per 100 000 in the Shetland and Orkney Islands of the North Atlantic contrasts with a prevalence approaching 1 per 100 000 in areas of Africa. These differences are not entirely due to variations in clinical sophistication or healthcare delivery, as once was assumed.

Data collected largely since World War II have demonstrated in Europe and North America a north/south difference in prevalence, with rates of 30–80 cases per 100 000 in northern Europe, southern Canada, and the northern United States, in contrast to rates of 6–20 per 100 000 in most of southern Europe and southern United States. The southern hemisphere is less well defined, but multiple sclerosis reaches moderate prevalence rates in South Africa, appears more common in southern than in northern Australia, and is more prevalent in the southern than in the northern island of New Zealand. The rate is higher for women than for men and half as frequent in African Americans as in white North Americans, although the same north/south gradient in the United States is seen in both races. Multiple sclerosis is a rare disease in Asians (Kurtzke, 1983, 2005).
This distribution has been interpreted as a latitude gradient, but it can also be viewed as three high-risk zones, including northern Europe and southern Scandinavia, northern United States and southern Canada, and New Zealand and south-east Australia. Each of these regions appears to be bounded by areas of medium frequency, with prevalence rates between 5 and 29 per 100,000, suggesting that multiple sclerosis may have risen in northern Europe, with subsequent establishment of foci among the descendants of migrants in the other locations (Kurtzke, 1983). Striking exceptions to the correlation of prevalence with latitude exist, such as the apparent absence of multiple sclerosis in Eskimos and a prevalence in excess of 150 per 100,000 in Sardinia (Montomoli et al., 2002). Whether prevalence in high-incidence areas has increased over time is uncertain. On the other hand, multiple sclerosis is now being reported in populations previously thought to be exempt from the disease such as American Indians, South African black populations, and European gypsies.

Migration studies
Following World War II, the majority of patients with multiple sclerosis in South Africa were immigrants from the United Kingdom or northern Europe, even though they made up less than 10% of the total population. Dean (1970) determined a prevalence rate for white Afrikaans-speaking natives of 3 per 100,000, for white English-speaking natives of 11 per 100,000, and for migrants from northern Europe of 50 per 100,000—the same order of magnitude seen in northern Europe. Further analysis indicated that migration prior to 15 years of age led to the same risk as that of native-born white South Africans, whereas migration after that age carried the risk of the birthplace (Dean and Kurtzke, 1971).

Similar studies in Israel indicated migrants from areas of high prevalence and low prevalence carried with them the risk of their country of origin, if they immigrated after the age of 15 (Alter and Kurtzke, 1968). Studies of immigration to Australia, Hawaii, and the Antilles all show similar high rates of disease of immigrants from high-risk areas (Kurtzke, 1983). Recent studies in French West Indies showed a higher prevalence in return immigrants from France if they had preadolescent “exposure” in France (Cabre et al., 2005).

In a matched-control study of veterans of World War II, residence of birth and at induction into the military showed a sharp north to south differential in risk of multiple sclerosis. Residence after induction and at onset of disease showed no significant correlation (Beebe et al., 1967). In a parallel case-control study of veterans of Vietnam and subsequent military service, interesting changes were found. Prevalence in women increased, prevalence in black men increased in comparison to white men, and the north–south gradient persisted but was less marked. Attenuation of the latitudinal gradient over time was also observed in the Nurses’ Health Study, which assessed multiple sclerosis incidence among female nurses in the United States born between 1921 and 1946. Although the initial study demonstrated that women born north of 41–42° north latitude had a 3.5-fold higher risk of multiple sclerosis compared to women born south of 37°, there was no such association in the follow-up Nurses’ Health Study II, which included nurses born between 1947 and 1964 (Hernan et al., 1999). A systematic review of over 38 studies from Europe, Australia, and the United States also found strong evidence for a recent diminution of the latitudinal gradient (Alonso and Hernan, 2008). Overall, these changes in gender, race, and geography over a short interval can be interpreted as strong evidence for environmental factors rather than genetic factors in the cause or precipitation of multiple sclerosis (Wallin et al., 2004).

Familial aggregation
Genes play an important role in multiple sclerosis. The most consistent association across all populations has been with the HLA-DRB1 gene, although an increasing number of genes of modest effect are being identified through genome-wide association studies (McElroy and Oksenberg, 2011). First-degree relatives of patients have a 3% lifetime risk. Twin studies have shown a higher concordance rate, between 14 and 25% in monozygotic twins and 2–5% in dizygotic twins (Willer et al., 2003; Hansen et al., 2005; Ristori et al., 2006). This suggests that up to 70% of determinants may be nongenetic. Recent analysis of adoptees, half-siblings, and step-siblings in the Canadian Network of Multiple Sclerosis Clincs showed no increase in prevalence in these family members, suggesting the environmental factor or factors were not in the familial microenvironment (Sadovnick, 2006). This would be an argument against microbes that spread from human to human but not those that spread by vectors or zoones.

Apparent epidemics
Rates of multiple sclerosis in Europe and North America have remained stable or increased gradually over years, but rates among inhabitants of north Atlantic islands of Norse ancestry have shown fluctuations, suggesting small epidemics. As mentioned above, the prevalence rates on the Orkney and Shetland Islands are the highest in the world, but analysis of cases suggests an abrupt increase in cases in the 1930s and an equally abrupt decline in cases in 1971 (Kurtzke, 2000).
By contrast, the neighboring Faroe Islands had been reported as having almost no multiple sclerosis. No cases were diagnosed before 1943; then 16 cases had onsets between 1943 and 1949, with several subsequent small waves of disease (Kurtzke et al., 1995). This gives the appearance of a point-source epidemic. The most unique antecedent event prior to 1943 was the 1940 occupation of the Faroes by the British, which leads to speculation that the disease was introduced by the British or their baggage. Detailed analysis showed a spatial relation between the homes of patients and the site of quartering of troops (Kurtzke, 2000). Notably, a recent examination of Danish National Health Service records of notifiable diseases in the Faroe Islands demonstrates a temporal association between acute gastrointestinal illness and the arrival of British troops (Wallin et al., 2010).

Multiple sclerosis has long been recognized in Iceland, but in view of the Faroe data, the year of onset of cases was re-examined. The disease appeared to occur at a steady low level until a sudden rise in 1923, which then plateaued until 1944, when there was a second rise that now is beginning to decline. Iceland was heavily occupied during World War II by Canadians and Americans as well as British military forces (Kurtzke et al., 1982).

Epidemiologic evidence of a specific virus

Human viral infections can be divided into three epidemiologic groups: those transmitted from human to human by enteric, respiratory, or venereal contact; those injected by hematophagous arthropods such as mosquitoes, ticks, or biting flies; and zoonoses, transmitted by the bite, exposure to, or consumption of animals that are the natural host of the virus.

The age of acquisition of an infection may influence the clinical manifestations. For example, poliomyelitis viruses seldom cause disease in infants, but cause more frequent and more severe paralysis at older ages. Thus, improved sanitation, that delays acquisition of this enteric infection, increases the risk of paralysis. Parallels between the epidemiology of multiple sclerosis and poliomyelitis have been made (Poskanzer et al., 1963). However, travel from high-risk to low-risk areas increases incidences of paralytic poliomyelitis, a phenomenon that is not seen with multiple sclerosis. Disease associated with improved sanitation should have a later and later onset of disease over the decades. Similar analogies with varicella-zoster virus have been made with its opposite distribution; early infection is prevalent in temperate zones, and infections are less common and of later onset at more tropical latitudes (Ross and Cheang, 1995). A more convincing argument has been made for Epstein–Barr virus (EBV), where early childhood infection in developing countries is not associated with clinical disease, whereas infection in adolescence and young adults is related to the clinical syndrome of infectious mononucleosis. Later but uniform infection with the virus and a more frequent history of infectious mononucleosis have been found in multiple sclerosis patients (see section on EBV, below). In several studies patients with multiple sclerosis were found to have a history of measles and other childhood diseases at later ages (Sullivan et al., 1984; Bachmann and Kesselring, 1998), but these findings were not confirmed in a more recent study that minimized recall bias (Bager et al., 2004). The notion that lack of certain infections owing to improved sanitation may lead to multiple sclerosis via inappropriate responses to innocuous substances or subsequent infections later in life has been formally conceptualized as the “hygiene hypothesis,” and has been proposed by some to underlie the higher incidence of multiple sclerosis in industrialized countries (Leibowitz et al., 1966; Fleming and Fabry, 2007). In support of this hypothesis, a small study demonstrated that parasitic infection can ameliorate the clinical course of multiple sclerosis and induce beneficial immune responses (Correale and Farez, 2007).

Arthropod-borne viruses show distinct geographic limitations, but these are even more sharply circumscribed than multiple sclerosis because of the localized distribution of the vectors. Furthermore, arboviral infections are highly seasonal, as are many of the viruses that are spread from human to human. If a virus had a latency from 3 to 30 years after infection, however, seasonality in initial exposure would be washed out by time.

Animal exposures have been evaluated in a number of studies. In the past there was an interest in a possible relationship to sheep. One retrospective epidemiologic study suggested an association with household dogs prior to the onset of symptoms of multiple sclerosis (Cook and Dowling, 1977). The authors linked their hypothesis to the Faroe data and postulated that British troops brought in canine distemper virus with their dogs (Cook et al., 1978). Similar distemper epidemics in Iceland were thought to correspond to increases in the incidence of multiple sclerosis, and cases of multiple sclerosis in Sitka, Alaska, 4–5 years after an outbreak of canine distemper, were reported (Cook and Dowling, 1984). Although apparent antibody to canine distemper virus can be found in human sera, this virus is closely related to measles, and reactions probably represent cross-reacting antibodies.

Viral infections and exacerbations

Patients with multiple sclerosis often relate exacerbations of disease to psychologic stress, physical trauma, or severe fatigue. Prospective studies have quite
consistently shown a more robust relationship with banal respiratory infections and exacerbations of multiple sclerosis (Buljevac et al., 2002). Most studies have not implicated a specific respiratory virus, and most regard these data as evidence that nonspecific antigenic stimulation can precipitate attacks. One serologic study did correlate adenovirus antibody increases with attacks but not influenza viruses (Anderson et al., 1993). Another study compared years of onset of multiple sclerosis to epidemic influenza data and found a correlation of increased disease onset with influenza virus activity (Kazmierski et al., 2004).

**VIRUS-INDUCED DEMYELINATING DISEASES OF ANIMALS AND HUMANS**

Several naturally occurring infections of animals are characterized by demyelination (Table 7.1). Laboratory infections of animals with human viruses or infections with adapted or genetically modified viruses have also shown variable amounts of demyelination, but these will not be addressed in this review. Two human demyelinating diseases clearly are caused by viruses, acute disseminated encephalomyelitis and progressive multifocal leukoencephalopathy, and the mechanisms of demyelination could not be more dissimilar. Other human viral infections, such as subacute sclerosing panencephalitis, human immunodeficiency virus (HIV) encephalopathy, and even herpes simplex encephalitis, are associated with variable amounts of myelin loss but are not considered primary demyelinating diseases.

Some of these virus-induced demyelinating diseases show how long latency periods can intervene between exposure to virus and the onset of clinical disease (lentiviruses in sheep and goats and progressive multifocal leukoencephalopathy in humans), some show mechanisms for relapsing and remitting courses of demyelination (lentiviruses in sheep and goats, Theiler’s virus in mice, and neurotropic mouse hepatitis virus), and all show different mechanisms of myelin loss.

Table 7.1

| Natural animal models of acute and chronic viral demyelinating diseases |
|---------------------------------------------------------------|
| **Lentivirus**        | Visna virus in sheep |
|                   | Caprine arthritis-encephalitis virus |
| Picornavirus        | Theiler’s virus in mice |
| Coronavirus          | JHM strain mouse hepatitis virus |
| Papovavirus          | SV40 in macaque monkeys |
| Paramyxovirus        | Canine distemper virus |

SV40, simian virus 40.

**Animal diseases**

**Visna and Caprine Arthritis-Encephalitis Viruses**

These natural virus infections of sheep and goats probably represent the best animal models for multiple sclerosis. They have an incubation period of months to years, may run a subacute or relapsing-remitting course of weeks to months, and give rise to focal areas of demyelination. They are caused by a subfamily of retroviruses called lentiviruses (the same subfamily that includes HIV) (Clements and Zink, 1996). Lentiviruses are unique in their ability to integrate their proviral DNA into postmitotic cells, particularly monocytes and macrophages. Antibodies appear to downregulate virus production, but frequent mutations of the virus cause relapses of disease. The same group of agents is also associated with chronic pneumonitis and arthritis (Narayan and Cork, 1985).

Visna is a progressive paralytic disease of sheep first recognized in Iceland (Sigurdsson and Palsson, 1958). It was experimentally transmitted by inoculation of the brains of affected sheep into other sheep with an incubation period of months to several years. The clinical course is progressive, but can occur in waves with static periods before later worsening. During this clinical disease, the animals are afebrile, but their spinal fluids show a pleocytosis and elevated protein (Nathanson et al., 1985). Leukoencephalomyelitis of goats is caused by a related virus, but this disease has a more rapid clinical course (Cork and Narayan, 1980). The encephalitis usually occurs in kids less than 6 months of age, and paralysis or death may ensue within weeks. Again, the animals are afebrile during the disease with a pleocytosis and elevated spinal fluid protein. Pathology in both diseases is characterized by multifocal white-matter lesions that are most prominent in the periventricular and subependymal areas. Demyelination occurs with axon preservation, but in severely involved areas there is leukomalacia with cavitation.

Visna viruses isolated late in the course of the incubation period or disease are not neutralized by the antibody formed against the initial infecting virus (Narayan et al., 1978). Virulent mutants arise within the persistently infected host that is not inactivated by neutralizing antibody formed against previous virus or mutants (Clements et al., 1980). Only cells of macrophage lineage are infected in the nervous system. The demyelination appears associated with an interferon-like molecule (a cytokine or lymphokine) released in the nervous system by infected macrophages and microglia (Narayan et al., 1983; Kennedy et al., 1985). The management of sheep and goats in laboratories and the lack of ruminant reagents for immunological studies have limited investigations of these models.
**Theiler’s Virus**

In 1934, Theiler recovered a virus from mice with naturally occurring acute flaccid paralysis. The virus is an enterovirus similar morphologically and epidemiologically to human polioviruses. These murine viruses, however, persist in the nervous system, and demyelination was found in chronically infected mice (Daniels et al., 1952). In 1975, Lipton reported that, after intracerebral inoculation of young mice, many developed acute paralytic disease with typical pathology of poliomyelitis, and virus antigen was shown in neurons; but about half of these animals survived. After intervals of 1–5 months, these survivors developed a progressive inflammatory myelopathy characterized by demyelination.

This unique biphasic disease has been widely studied. The acute paralytic disease is clearly associated with the infection and destruction of motor neurons. The mechanism of the late demyelination involves persistent infection, and both macrophages and oligodendrocytes are infected (Brahic et al., 2005; Lipton et al., 2005). Immunosuppression with cyclophosphamide or antithymocyte serum prevents the late demyelination, however, suggesting that demyelination is immune-mediated (Lipton and Dal Canto, 1976). Indeed, in vivo depletion and neutralization studies have suggested important roles for both CD4+ and CD8+ T cells in mediating Theiler’s murine encephalomyelitis virus-induced demyelination (Tsunoda and Fujinami, 2010).

The phenomenon of epitope spreading was found in studies of chronic Theiler’s virus infections in specific strains of mice. In the course of glial cell infection, cell-mediated immune responses develop against myelin epitomes. Thus, although the initial response is directed against the virus, the response broadens with myelin proteins becoming targets. In this model of demyelinating disease persistence of infection would not be necessary to maintain recurrent or progressive disease (Katz-Levy et al., 1999; Tompkins et al., 2002).

**Neurotropic Mouse Hepatitis Virus**

This virus was originally isolated from laboratory mice with spontaneous hind-leg paralysis (Cheever et al., 1949); histologic studies showed patchy areas of demyelination with sparing of axons in brain and spinal cord (Bailey et al., 1949). In 1969, Weiner obtained the virus from the original laboratory and showed that, with manipulation of dosage of virus, age of mice, and route of inoculation, demyelinating lesions could be produced consistently. Immunocytochemical staining showed that virus antigen was predominantly in glial cells of the white matter. The mechanism of demyelination did not appear to be immunopathologic, since immunosuppression with cyclophosphamide did not prevent demyelination (Weiner, 1973). Ultrastructural studies suggested a direct lytic infection of oligodendrocytes (Lampert et al., 1973).

Although the virus was found to persist in the nervous system, the evident clinical disease was a uniphasic demyelinating process associated with selective infection of oligodendrocytes. However, in studies of remyelination it was noted that new areas of subclinical demyelination appeared to be developing concurrently with remyelination of older lesions (Herndon et al., 1975, 1977). The pathogenesis appears to be complex, with studies showing that late demyelination does not occur in mice lacking B or T cells, but does occur with transfer of virus-specific T cells or virus-specific antibodies (Stohlman and Hinton, 2001; Kim and Perlman, 2005). In addition, both monocyte-derived macrophages and microglia are present in regions of demyelination and can be observed to contact demyelinating axons (Templeton et al., 2008; Bender and Weiss, 2010). Thus, acute demyelination may be caused by direct lysis of oligodendrocytes, but persistent viral infection of glial cells may be capable of initiating humoral and cell-mediated immune responses that cause exacerbations of demyelination.

**Other Natural Infections Causing Demyelination**

Progressive multifocal leukoencephalopathy morphologically and ultrastructurally simulating the human disease has been found in macaque monkeys at a primate colony (Gribble et al., 1975). All animals had underlying diseases probably leading to immunodeficiency, such as lymphoma, giant cell pneumonia, or colitis. SV40 virus, a simian polyomavirus, was recovered from brains. Experimental infection of monkeys with an immunodeficiency virus and SV40 has been associated with inflammatory encephalitis as well as demyelination (Axthelm et al., 2004).

Canine distemper is caused by a morbillivirus related to measles. It is an acute respiratory and gastrointestinal disease in dogs often complicated by central nervous system disease that may occur acutely or weeks or months after recovery from the acute illness (McCullough et al., 1974). During the acute infection the dog is immunosuppressed, and there is little inflammatory response. Viral persistence, which is thought to underlie progression of inflammatory demyelination, is achieved through noncytolytic cell-to-cell spread, as demonstrated in astrocytes (Wyss-Fluehmann et al., 2010). Initiation of demyelination was previously presumed to follow glial cell lysis,
but may in fact result from metabolic insufficiency of oligodendrocytes (Sips et al., 2007). In the late demyelina-
tion or relapses of disease, intense inflammation is
found in the white matter. A paucity of viral antigen is
found, but viral nucleocapsid structures have been iden-
tified in glial cells in the brain (Raine, 1976). Recent stud-
ies suggest that chronic inflammatory demyelination
results from interactions between macrophages and anti-
viral antibodies (Vandevelde and Zurbriggen, 2005).

**Human demyelinating diseases**

**ACUTE DISSEMINATED ENCEPHALOMYELITIS**

This is an acute perivascular demyelinating disease of the
brain and spinal cord. In most patients it erupts abruptly
days or several weeks after a viral exanthem or virus-like
illness, but the disorder is not specific to viruses and has been
seen after some bacterial illness, immunizations,
and drug and serum therapies (Noorbakhsh et al.,
2008). Fifty years ago it was estimated that one-third
of all cases of clinical encephalitis were postinfectious.
The commonest cause was measles, which, along with
cases rarely associated with rubella and mumps, has been
largely eliminated in regions where children are pro-
tected by the measles-mumps-rubella (MMR) vaccine.
The second major cause of acute disseminated encephalo-
myelitis was a vaccine, vaccinia virus, which was aban-
donned after the worldwide eradication of smallpox in
1977. More recently the varicella-zoster vaccine has fur-
ther reduced the risk of this disease. It is now estimated
that less than 10% of cases of encephalitis represent
acute disseminated encephalomyelitis. This exhibits a
remarkable success in disease control by both introduc-
ing and eliminating immunizations (Johnson, 1994;
Johnson and Major, 2004). The pathologic appearance
is remarkably similar to that in the neuroparalytic com-
plication in postexposure rabies vaccination and experi-
mental allergic encephalomyelitis (Johnson et al., 1985).

After measles, this complication occurs in about 1 per
1000 cases, with a mortality rate of about 20% and a
high rate of sequelae in survivors. Measles virus is
known to infect peripheral blood leukocytes and to alter
immune responses. The frequent secondary infections
are thought to result from immunosuppression, yet the
encephalomyelitis is assumed to represent a hypersensitiv-
ity response. Antibody response to measles virus is nor-
mal in both uncomplicated measles and measles
encephalomyelitis, but lymphocytes from patients with
measles show prolonged suppression of lymphoproliferative responses to mitogens. This occurs to an equal degree
in uncomplicated measles, measles complicated by sec-
ondary infections, and measles with encephalomyelitis
(Hirsch et al., 1984). The failure of mitogen responses
and normal immune regulation appear to result from
immune activations by the infection (Griffin et al.,
1989). One result of this activation is the finding that a
large percentage of patients with encephalomyelitis have
lymphocyte proliferative responses in the presence of
human myelin basic protein (Johnson et al., 1984), a find-
ing analogous to that in experimental allergic encephalo-
myelitis. Thus, it appears that measles may interrupt the
normal regulatory mechanisms that prevent responses to
self-antigens.

In measles encephalomyelitis, induction of autoim-
mune disease may occur without virus invasion of the
nervous system. During acute measles virus can be
found in a number of organs (Moench et al., 1988) but
only in endothelial cells in the central nervous system
(Esolen et al., 1995). The virus is cleared by the time
encephalomyelitis develops, and virus cannot be isolated
from the brain or spinal fluid, intrathecal synthesis of
immunoglobulins against measles virus is not found
(Johnson et al., 1984), and immunocytochemical staining
fails to demonstrate measles virus antigen in the brains
of patients dying at various intervals after measles
encephalomyelitis (Gendelman et al., 1984). Thus, in this
acute demyelinating disease, viral infection of peripheral
immunocompetent cells appears to be the primary event;
this leads to deregulation of normal suppression of
responses against myelin proteins, and demyelination
occurs without direct viral infection of neural cells
(Johnson et al., 1985).

**PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY**

Progressive multifocal leukoencephalopathy is a sub-
acute multifocal demyelinating disease usually compli-
cating disease of the reticuloendothelial system or
immunosuppression administered to maintain organ
allografts or to treat other diseases. It was an exceed-
ingly rare disease until the epidemic of HIV began in the
1980s. By the mid-1990s approximately 4% of patients
dying of acquired immunodeficiency syndrome (AIDS)
had progressive multifocal leukoencephalopathy. With
the routine use of highly active antiretroviral therapy
in 1996, incidence and death rates of progressive multi-
focal leukoencephalopathy have gradually declined,
though not reaching pre-epidemic levels (Christensen
et al., 2010). The demyelinated foci show a loss of oligo-
dendrocytes. Surrounding the demyelinated areas, the
oligodendrocytes are enlarged and contain intranuclear
Mechanisms of virus-induced demyelination

Viruses can cause demyelination by a variety of mechanisms (Table 7.2). Some of these are documented; some remain theoretical. Virus replication in oligodendrocytes can produce acute or chronic demyelinating disease, as seen in the acute lesions due to neurotropic mouse hepatitis virus or the subacute demyelination in progressive multifocal leukoencephalopathy. Theoretically, toxic effects of virus proteins alone might cause demyelination without immune responses or selective infection of oligodendrocytes.

Most virus-induced demyelinating diseases appear to involve immune responses, but in lentivirus, Theiler’s virus, and murine hepatitis virus infections, each has a different twist in the mechanism of demyelination. In viral infections with most enveloped viruses, virus-specified polypeptides were inserted in the plasma membrane of the host cell. If the oligodendrocytes are infected, antibody or cell-mediated immune reactions against these antigens could lead to oligodendrocyte lysis and demyelination. Alternatively, virus infection of the myelin-supporting cells could release myelin antigens into the circulation or myelin antigens could be incorporated into the virus envelope, and the virus would act as a vehicle to induce autoimmunity. The latter mechanism may initiate epitope spreading and recurrent autoimmune demyelination.

Molecular mimickry, in which a cross-reaction occurs between an environmental factor (such as a virus) and a host antigen (such as a myelin protein), has been a popular hypothesis. In this scenario demyelinating disease could result from systemic or other organ system infections without involvement of the nervous system. This has not been incriminated in the diseases above, but sequence homologies between the nuclear ribonuclear neuronal protein in human nervous system and the tax protein of human T-lymphotropic virus-I (HTLV-I) virus has been implicated in cellular damage in HTLV-I-associated myelopathy (Levin et al., 2002).

### Table 7.2

**Possible mechanisms of virus-induced demyelination**

| **Direct viral effects** |  |
|-------------------------|--|
| Virus infection of oligodendrocytes causing demyelination through cell lysis or an alteration in cell metabolism |  |
| Myelin membrane destruction by viral proteins |  |

| **Virus-induced immune-mediated reactions** |  |
|-------------------------------------------|--|
| Antibody or cell-mediated reactions to viral antigens on cell membranes |  |
| Sensitization of host to myelin antigens (epitope spreading) |  |
| Breakdown of myelin by infection with release into the circulation |  |
| Incorporation of myelin antigens into virus envelope |  |
| Modification of antigenicity of myelin membranes |  |
| Cross-reacting antigens between virus and myelin proteins (molecular mimickry) |  |
| Cytokine or protease demyelination (bystander effect) |  |

**Viral disruption of regulatory mechanisms of the immune system**

- Modified from Johnson (1985).
In support of this hypothesis in the pathogenesis of multiple sclerosis, a single T-cell receptor from a multiple sclerosis patient was found to recognize peptides from myelin basic protein and EBV complexed with common multiple sclerosis-associated major histocompatibility complex (MHC) class II alleles (Lang et al., 2002). Similar cross-reactivity has been observed between human herpesvirus-6 (HHV-6), influenza, and human coronavirus peptides and myelin epitopes, emphasizing the promiscuity of T cell–peptide interactions that may promote autoimmunity following infection (Tejada-Simon et al., 2003; Markovic-Ples et al., 2005; Boucher et al., 2007).

Demyelination due to soluble molecules released by inflammatory cells (cytokines and lymphokines or proteases) has been called the “innocent bystander effect.” This was originally described with the demyelination surrounding an intracerebral tuberculin reaction and related to proteases released by activated lymphocytes or macrophages (Cammer et al., 1978). In visna virus leukencephalitis the myelin destruction appears related to infected macrophages and microglia with release of a toxic signal molecule (Kennedy et al., 1985). Many glial-derived molecules have been implicated in inflammatory demyelination and neuronal injury, including tumor necrosis factor-α, interleukin-1, interleukin-6, and nitric oxide (Gandhi et al., 2010).

Finally, virus-induced demyelination may not necessitate viral infection of the nervous system or involve molecular mimickry. In acute disseminated encephalomyelitis, infection of lymphoid cells disrupts normal immune regulation. In the state of normal health lymphocyte traffic through the central nervous system is limited and restricted largely to activated cells. In measles two factors increase the risk of autoimmune disease: first, the lack of downregulation of self-reacting cells and second, the activation of lymphocytes increasing traffic into the nervous system.

**STUDIES OF PATIENTS IMPLICATING VIRUSES**

Studies of patients with multiple sclerosis by serologic and virus detection methods have implicated poxviruses, herpesviruses, rhabdoviruses, orthomyxoviruses, paramyxoviruses, coronaviruses, togaviruses, flaviviruses, adenoviruses, picornaviruses, papovaviruses, retroviruses, and a variety of uncharacterized putative agents. Thus, almost the full gamut of viruses has, at one time or another, been suspected in multiple sclerosis. Occasional bacterial and parasitic agents have been implicated, but these claims have been sparse by comparison. Viruses have been incriminated by immunologic studies of patients, electron microscopic examination of brain lesions, reports of virus isolation, demonstration of viral nucleic acids by polymerase chain reaction (PCR), or demonstration of laboratory effects on tissue cultures or animals thought to indicate the presence of a virus.

**Antibody studies**

In 1962, Adams and Imagawa reported that antibody titers against measles virus were higher in patients with multiple sclerosis than in controls. Measles antibodies were detected in cerebrospinal fluid of over 75% of the patients with multiple sclerosis and not in controls. These startling findings soon were confirmed in over 30 subsequent studies. These confirmatory studies also found higher levels of serum antibodies against many other viruses, but the results were less consistent and less robust than the findings of measles antibodies (Norrby, 1978; Bray et al., 1983). Studies comparing levels of antibody in spinal fluid with those in serum rather consistently showed intrathecal synthesis of antibodies against measles virus, but abnormalities in the serum/spinal fluid antibody ratios have also been found for a wider spectrum of agents (Table 7.3). In one study, 23% of patients with multiple sclerosis had disproportionately high spinal fluid antibodies to two or more viruses (Norrby et al., 1974); in another study, simultaneous intrathecal synthesis occurred to as many as 11 different agents in the same patient (Salmi et al., 1983). In discordant twin studies higher serum and spinal fluid levels of antibody are usually found in the affected twin (Kinnunen et al., 1990).

**Table 7.3**

Higher antiviral antibodies in multiple sclerosis than in controls

| Serum                  | Cerebrospinal fluid |
|------------------------|---------------------|
| Measles                | Measles             |
| Parainfluenza 2, 3     | Parainfluenza 1, 2, 3|
| Influenza A, C         | Influenza A, B      |
| Varicella              | Varicella           |
| Herpes simplex         | Herpes simplex      |
| Human herpes virus-6   | Human herpesvirus-6 |
| Epstein–Barr           | Epstein–Barr        |
| Rubella                | Rubella             |
| Mumps                  | Respiratory syncytial|
| Coronaviruses          | Coronaviruses       |
| Adenoviruses           | Adenoviruses        |
| Borna disease virus    | Borna disease virus |
| HTLV-I (gag)           | HTLV-I (gag)        |
| HTLV-II                | Simian virus-5      |
| Human herpesvirus-6    | Human herpesvirus-6 |

HTLV, human T lymphotropic virus.
These findings might suggest that multiple viruses can cause multiple sclerosis or that preprogrammed B cells are nonspecifically activated or released from immune regulation after entering the brain (Cremer et al., 1980). Studies of responses to one protein of a virus and not another and studies of antibody-variable regions suggest a more specific response (Nath and Wolinsky, 1990). It is important to note that the finding of higher serum antibody titers to measles is not disease-specific; similar findings have been reported in lupus erythematosus, Reiter’s syndrome, and chronic hepatitis. Also measles infection is not a prerequisite for disease, since measles has been reported to occur after the onset of multiple sclerosis.

The studies of antibody levels have uniformly showed enhanced responses to viral antigens in multiple sclerosis patients and the intrathecal synthesis of antiviral antibodies. The preponderance of data implicate measles virus and not another and studies of antibody-variable regions suggest a more specific response (Nath and Lampert, 1975). None of these particles is specific for, or consistent in, multiple sclerosis, and none has been identified as viral in nature.

**Electron microscopic studies**

In the 1970s a number of electron microscopic studies of autopsy and biopsy tissue of patients with multiple sclerosis were reported to show “virus-like” particles. These included: (1) ovoid membrane bodies 30–200 nm in diameter, which are now thought to represent myelin breakdown products; (2) dense intracytoplasmic osmiophilic granules of 60–80 nm in diameter surrounded by membrane, which are thought to be nonspecific changes in reactive astrocytes (Andrews and Andrews, 1973; Kirk, 1979); and (3) intranuclear structures in inflammatory cells, which were initially thought to represent myxovirus nucleocapsids and are now believed to be nonspecific alterations of nuclear chromatin (Lampert and Lampert, 1975). None of these particles is specific for, or consistent in, multiple sclerosis, and none has been identified as viral in nature.

**Virus isolations**

Interest in specific viruses in multiple sclerosis was stimulated by the report in 1946 from the Soviet Union that viruses had been isolated in mice from 2 patients with multiple sclerosis: one from the blood of the patient and the other from cerebral tissue (Margulis et al., 1946). These viruses, however, were identified in other laboratories as rabies virus, and antibody was not found against the agent in the sera of patients (Dick et al., 1958). Nevertheless, the same laboratory later reported further isolates of similar agents (Bychkova, 1964) (Table 7.4). The isolation of a herpes simplex virus from brain tissue of a patient was reported from Iceland (Gudnadottir et al., 1964), but this isolate was subsequently characterized as a type 2 herpes simplex virus, a virus known to reactivate intermittently in the nervous system, causing recurrent meningitis.

The report of the induction of scrapie in Icelandic sheep 16–20 months after the intracerebral inoculation of multiple sclerosis brain now appears to have resulted from the contamination of a shipping container. A further link between scrapie and multiple sclerosis was raised by the report of the diminution of mouse polymorphonuclear cells and inhibition of cell culture growth by inoculation of homogenates of tissue of scrapie and multiple sclerosis. These findings were not verified in controlled studies (Brown and Gajdusek, 1974; Carp et al., 1977).

The isolation of parainfluenza type 1 virus from tissue culture derived from 2 patients dying of multiple sclerosis was pursued extensively and unsuccessfully. The recovery of measles from a single patient was interpreted in the original report as a probable laboratory contamination, and tests for measles viral proteins and genetic material by other methods have failed to show evidence of measles in brains of multiple sclerosis patients (Stevens et al., 1980; Hall and Choppin, 1982).

Cytopathic agents have been reported from bone marrow and from cerebrospinal fluids of patients by inoculation of MRC-5 human diploid cells. In the first of these studies, the cells were found to be contaminated with Mycoplasma (Mitchell et al., 1979), which might explain the cytopathology. Subsequently the authors reported that there was a virus that they identified as simian virus 5. However, serologic studies showed no indication of an etiologic relationship between simian virus 5 and multiple sclerosis (Goswami et al., 1984). Another putative agent was reported in MRC-5 cells inoculated with spinal fluid from 3 patients with multiple sclerosis and one with amyotrophic lateral sclerosis (Melnick, 1982). Attempts at confirmation have been unsuccessful.

A simian cytomegalovirus was recovered from a chimpanzee inoculated neonatally with brain cells from a patient, but the clinical disease that developed in the chimpanzee suggested an acute polyneuropathy that may or may not have been related to the simian agent. The recovery of coronaviruses from mice inoculated with brains of patients dying of multiple sclerosis was of interest in view of the observations that a murine coronavirus can cause remitting and relapsing demyelinating disease in mice. Subsequent studies of these isolates, however, have shown that they share extensive nucleotide homology with murine coronaviruses, suggesting that they are of mouse rather than of human origin (Weiss, 1983). The recovery of a flavivirus, tick-borne encephalitis virus, in mice also can be assumed to be a contaminate, since hundreds of similar mouse inoculations have not yielded similar results (Vagabov et al., 1982).
HTLV-I virus sequences were reported in cells cultured from spinal fluids of patients with multiple sclerosis (Koprowski et al., 1985), but a number of attempts to confirm these studies failed. Sequences of JC virus were reported by direct PCR on spinal fluid in 11 of 121 multiple sclerosis patients (Ferrante et al., 1998). In a more recent study, however, virus was rarely detected and, when present, viral copy numbers were low (Iacobaeus et al., 2009). PCR examination of spinal fluid for JC has become a routine procedure for diagnosis of progressive multifocal leukoencephalopathy, where it has proved highly specific, although of variable sensitivity (Ryschkewitsch et al., 2004).

Agents of recent interest

Over the past two decades, since the prior Handbook edition (Johnson, 1985), virologic interest has shifted to the pathogenic role of endogenous or latent human agents rather than an “exogenous multiple sclerosis agent.” Recent reports have focused on herpesviruses (particularly EBV and HHV-6), endogenous retroviruses, and a bacterium, Chlamydia pneumoniae. All represent ubiquitous agents that persist in humans and might be regarded as “normal flora.” Therefore, rather than seeking a novel agent, epidemiologic, virologic, and immunocytochemical studies have focused on the timing and

### Table 7.4

| Virus                              | Isolation method                                                                 | Reference          |
|------------------------------------|---------------------------------------------------------------------------------|--------------------|
| Rabies virus                       | Encephalitis in mice inoculated with brain or blood                              | Margulis et al. (1946) Bychkova (1964) Gudnadottir et al. (1964) |
| Herpes simplex virus               | Cytopathic changes in cell culture inoculated with homogenate of brain           |                    |
| Scrapie agent                      | Scrapie developed in sheep 16–21 months after inoculation with brain             | Palsson et al. (1965) |
| Multiple sclerosis-associated agent| Decrease in polymorphonuclear cells in mice inoculated with multiple sclerosis tissue | Carp et al. (1972) |
| Parainfluenza virus 1              | Cell cultures of brain tissue of 2 patients fused with other cells and virus recovered | ter Meulen et al. (1972) |
| Measles virus                      | Cytopathic changes in monkey kidney cells inoculated with homogenate of brain biopsy | Field et al. (1972) |
| Simian virus 5                     | Syncytia formed in MRC5 cell cultures inoculated with patients’ bone marrow cells | Mitchell et al. (1978) |
| Chimpanzee cytomegalovirus         | Neonatal chimpanzee inoculated with brain cells of patient developed paralysis 3 years later | Wrobleska et al. (1979) |
| Coronavirus                        | Fresh unfrozen brains inoculated into mice and grown in cultured yielded virus   | Burks et al. (1980) |
| SMON-like virus                    | Cytopathic changes on MRC5 inoculated with CSF                                  | Melnick et al. (1982) Vagabov et al. (1982) |
| Tick-borne encephalitis virus      | Blood from 2 patients inoculated intracerebrally into mice                       |                    |
| HTLV-I                             | RNA sequences in CSF cells of 4 of 8 patients                                   | Koprowski et al. (1985) Perron et al. (1989) |
| LM7 (retrovirus)                   | Found in leptomeningeal cell line from CSF                                      |                    |
| Herpes simplex virus, type 1       | Isolated from CSF during first attack                                            | Bergstrom et al., 1989 |
| Human herpesvirus-6                | Viral DNA in CSF of several patients                                            | Wilborn et al. (1994) |
| JC virus                           | PCR detection of DNA in CSF                                                     | Ferrante et al. (1998) |

SMON, subacute myelo-optical neuropathy; HTLV, human T lymphotropic virus; CSF, cerebrospinal fluid; PCR, polymerase chain reaction.
prevalence of acquisition and on the quantitation and cellular localization of these infections. In each case the difficult question is whether changes are related to causation or are secondary to immunologic changes inherent in multiple sclerosis (Johnson and Major, 2004).

**Epstein–Barr Virus**

Infection with this virus is almost universal, and the virus persists in latent form in B cells. In tropical and impoverished areas of the world, where multiple sclerosis prevalence is low, infection occurs in childhood and is essentially asymptomatic. In temperate zones and developed countries infection is delayed in many until adolescence or young adult years, and in these cases primary infection may be manifest by the clinical syndrome of infectious mononucleosis. In numerous cohort and case-control studies a history of infectious mononucleosis was more frequent in patients with multiple sclerosis, and a recent meta-analysis estimates that infectious mononucleosis doubles the risk of multiple sclerosis (Handel et al., 2010). In many serologic studies multiple sclerosis patients are virtually uniformly positive for antibodies to EBV before onset of neurologic symptoms, although prior infection is not a prerequisite for development of disease in the pediatric population (Matyn et al., 1993; Haahr et al., 1995; Ascherio and Munch, 2000; Levin et al., 2003; Pohl et al., 2006; Banwell et al., 2007). A prospective study showed that persons who will develop multiple sclerosis exhibit an altered immune response against EBV with a high IgG activity to Epstein–Barr nuclear antigen (EBNA-1) in the absence of high activity to virus capsid antigen (VCA), and this is pronounced in the 5 years before clinical onset of multiple sclerosis (Sundstrom et al., 2004). In many other studies, serum antibodies to both VCA and EBNA1 are elevated. Notably, both seroprevalence and titers of antibodies to EBNA1 and VCA are increased in pediatric multiple sclerosis cases, indicating that infection precedes multiple sclerosis even in cases of early-onset multiple sclerosis (Pohl et al., 2006; Banwell et al., 2007). A recent meta-analysis that included numerous case-control studies of antibodies to EBV antigens found odds ratios of over 12 for EBNA-1 and over 5 for VCA seropositivity in multiple sclerosis patients compared to controls (Santiago et al., 2010).

Although serologic studies have consistently demonstrated evidence of past infection, there is little evidence for active infection or reactivation of EBV in patients with multiple sclerosis. Neither the presence nor quantity of viral DNA in plasma, peripheral blood-derived mononuclear cells, or whole blood has been consistently increased in individuals with multiple sclerosis (Santiago et al., 2010; Lucas et al., 2011). Although some longitudinal studies have found an association between virus activation and disease activity in multiple sclerosis patients, others have not confirmed this, finding instead an association between titers of EBNA-1 and clinical and radiologic markers of disease activity (Wandinger et al., 2000; Torkildsen et al., 2008; Farrell et al., 2009).

In many nervous system infections antibodies are generated intrathecally, giving rise to oligoclonal bands of antibody in spinal fluid; these bands are typically present in multiple sclerosis, but the target antigen remains a mystery. In some multiple sclerosis patients these bands have been reported to bind to EBNA (Rand et al., 2000), while more recent studies suggest that, when present, oligoclonal EBV-specific responses are often systemic in origin and are found in a wide variety of neurologic disorders (Franciotta et al., 2010).

Several provocative reports have described patients with neurologic complication of acute EBV infections who went on to develop progressive or relapsing disease, diagnosed as multiple sclerosis (Shaw and Alvord, 1987; Bray et al., 1992). Another describes a 6-year-old with 11 episodes of relapsing disease and high titers of Epstein–Barr antibodies. At autopsy typical multiple sclerosis lesions were found, and PCR of brain showed EBV sequences (Pedneaukt et al., 1992). Laser capture microdissection of meninges and white-matter lesions from multiple sclerosis brains followed by reverse transcription PCR has demonstrated the presence of EBV latency-associated genes in inflamed tissue (Serafini et al., 2010). In addition, EBV-encoded RNAs (EBERs), the small noncoding RNAs which are abundantly expressed in lately infected cells, have been found in multiple sclerosis lesions via *in situ* hybridization, although they are also present in cases of stroke (Tzartos et al., 2012). These findings in brain or spinal fluid are difficult to interpret, since EBV is latent in B cells. B cells are rare in normal brain or spinal fluid but do enter in inflammatory diseases (and are present in the lumen of vessels in brain sections). Demonstration of the virus in neural cells would provide stronger evidence for a causal relationship between this virus and multiple sclerosis.

**Human Herpesvirus-6**

This herpesvirus was recently recognized and associated with exanthem subitum (roseola infantum). Between 70 and 100% of adults have serologic evidence of past infection. The virus is latent primarily in T lymphocytes, but is more pleiotropic than other herpesviruses and has been reported in B cells and central nervous system glial cells in people without neurological disease (Soldan et al., 2001). Human herpesvirus-6 isolates have been subdivided into type A and type B. Type B variants have
been the predominant isolates from childhood exanthems, and the isolates in multiple sclerosis studies have been predominantly type A variants.

Initial observations of higher antibody levels in serum and presence of antibodies in spinal fluid were similar to other viruses. However, DNA was detected in spinal fluid by PCR (Wilborn et al., 1994), and the following year herpesvirus-6 DNA was reported in the majority of multiple sclerosis and control brains (Challoner et al., 1995). However, immunocytochemical staining showed a change of distribution: in normal brains virus antigen was found primarily in meningeal cells, but in multiple sclerosis lesions, adjacent cells, thought to represent neurons and oligodendrocytes, were positive. Subsequent studies have shown remarkable variance; some have correlated virus in blood or spinal fluid with disease activity (Alvarez-Lafuente et al., 2004), whereas others have not. Different IgG and IgM responses have been reported, but other reports have failed to confirm this finding (Virtanen and Jacobson, 2012). The frequency of detectable virus in brain and the correlation with disease have been extreme, from reports of lack of detectable virus in diseased or normal brain tissue, to a claim that 90% of active multiple sclerosis lesions were positive for viral antigen while positive staining was found in only 13% of brain sections without active disease (Knox et al., 2000). Utilizing laser capture microdissection followed by PCR, Cermelli and colleagues (2003) found that herpesvirus-6 DNA was detected far more frequently in multiple sclerosis plaques as compared to normal-appearing white matter from multiple sclerosis patients or from controls. Using in situ PCR, Goodman and colleagues (2003) showed herpesvirus-6 genome in numerous oligodendrocytes as well as lymphocytes and microglia in acute multiple sclerosis lesions. Also with in situ PCR, Opsahl and Kennedy (2005) have shown herpesvirus-6 gene transcription in oligodendrocytes in multiple sclerosis patients’ normal-appearing white matter, lesional tissue, and normal control brain sections. Viral mRNA was higher in white matter and lesions of patients, and viral gene expression was higher in samples from lesions.

The presence of this and other herpesvirus in nervous system cells seems well established. Activation of herpes simplex viruses, varicella-zoster, and human herpesviruses-7 and 8 have also been correlated with disease activity (exacerbations) in multiple sclerosis (Sanders et al., 1996; Tomstone et al., 2001; Ordonez et al., 2004; Pietropaolo et al., 2005; Kang et al., 2011). Therefore, the activation of human herpesviruses lacks specificity. Activation or spread coincident with attacks of multiple sclerosis may represent a trigger or cause of the attack or may represent a secondary, nonspecific activation of latent herpesviruses.

**Endogenous retroviruses**

Human endogenous retroviruses (HERVs) are DNA sequences within human chromosomes; they comprise up to 8% of the human genome. The characteristic presence of long terminal repeats followed by gag, pol, and env genes identifies their retroviral origins. These sequences are thought to represent ancestral infections in which integrated DNA is now passed on in Mendelian fashion. Comparisons to ERVs of apes and old world monkeys suggest that some entered our genome 25 million years ago (Voisset et al., 1999). No endogenous retrovirus has been convincingly linked to human disease, but the potential to enhance downstream cellular genes has led to speculation that they might be important in autoimmune diseases such as multiple sclerosis, Sjögren’s disease, systemic lupus erythematosus, and type 1 diabetes (Perron and Seigneurin, 1999).

In 1989 Perron and colleagues reported evidence of a retrovirus in a cell line of meningeal cells grown from spinal fluid of a patient with multiple sclerosis. Subsequently his group analyzed monocytes from patients and controls and reported evidence of retroviral activity or retrovirus particles in the majority (Perron et al., 1991). Recognition that the viral elements were endogenous, as opposed to an exogenous retrovirus, resulted in coinage of the name “multiple sclerosis-associated retroviral element” (MSRV). Several other laboratories have found similar HERVs in blood and spinal fluid of multiple sclerosis patients, and the presence of MSRV in the cerebrospinal fluid of patients with multiple sclerosis has been associated with a greater rate of disease progression (Sotgiu et al., 2010). Although similar activity has also been found in other inflammatory neurologic diseases and schizophrenia, the frequency of HERV detection has generally been more frequent in multiple sclerosis (Dolei et al., 2002; Dolei, 2005). Of the over 30 HERV families named according to the one-letter code of the transfer RNA used to prime reverse transcription, HERV-W, HERV-K, and HERV-H have been most frequently associated with multiple sclerosis (Antony et al., 2011). Much recent attention has focused upon HERV-W, of which MSRV is a member. In addition, the protein syncytin-1, a glial protein that induces neuroinflammation and is expressed more frequently in multiple sclerosis than control brains, is derived from an envelope gene of HERV-W (Antony et al., 2004). Retroviral protein and virion production has been postulated to result from interactions with other viruses, including herpesviruses (Christensen, 2005). Specificity was further questioned in studies that showed HERV RNA levels increased with stimulation of macrophages in culture, and in brain in patients with HIV encephalopathy as well as in multiple sclerosis (Johnston et al., 2001). This study suggests that
immune activity enhances viral expression rather than being a cause of the immune activation.

**CHLAMYDIA PNEUMONIAE**

*C. pneumoniae* is an obligate intracellular Gram-negative bacterium. It is a common respiratory pathogen; 40–70% of adults have antibody, with most seroconversion occurring during adolescence. The bacteria persist in macrophages, and the attempts to relate the bacterium to chronic diseases such as atherosclerosis and multiple sclerosis are confounded by the possibility that the agent is simply carried into inflammatory lesions by infiltrating macrophages.

After the recovery of *C. pneumoniae* from the spinal fluid of a patient with multiple sclerosis, Sriram and coworkers (1999) carried out an extensive study using culture and PCR methods. They reported positive cultures in 64% of multiple sclerosis patients and only 11% of control patients, and positive PCR results in 97% of multiple sclerosis patients and only 18% of patients with other neurologic diseases. They subsequently reported that oligoclonal bands in spinal fluid could be partially or completely adsorbed by *C. pneumoniae* antigens (Yao et al., 2001). These reports have been followed by a plethora of reports partially confirming or refuting the results, but none with the robust results of the initial report. In a subsequent report, for example, PCR detected *C. pneumoniae* in 21% of multiple sclerosis patients, 43% of patients with other neuroinflammatory diseases, and none in healthy controls (Gieffers et al., 2001). A prospective serologic study of several large US populations showed that neither seropositivity to *C. pneumoniae* nor level of antibody predicted risk of developing multiple sclerosis (Munger et al., 2004). However, a meta-analysis examining over 70 studies found that multiple sclerosis patients were more likely to have detectable levels of *Chlamydia* DNA in their cerebrospinal fluid and intrathecally synthesized immunoglobulins compared to other patients with neurologic diseases (Bagos et al., 2006). A recent small study found that *C. pneumoniae*-specific intrathecal immunoglobulins were found more frequently in patients with progressive, as compared to remitting-relapsing, forms of multiple sclerosis (Fainardi et al., 2009). Overall, these reports support the hypothesis that the bacteria are passively carried into the nervous system when host macrophages traffic into inflammatory responses.

**Infections in the context of host genetics**

It has long been recognized that multiple sclerosis may arise as a result of interactions between environmental triggers and host genetic factors, the combination of which may influence disease susceptibility or expression. Much interest has focused on interactions between the strongest identified genetic risk factor for multiple sclerosis, HLA-DRB1*15, and viral exposure. The presence of high EBNA1 antibody titers was associated with a higher risk for multiple sclerosis among HLA-DRB1*15-positive individuals as compared with DRB1*15-negative individuals (Sundstrom et al., 2008), although several subsequent studies have not confirmed a direct interaction (De Jager et al., 2008; Waubant et al., 2011). Another major histocompatibility gene locus, HLA B7, was associated with increased anti-EBV VCA levels and worse radiologic markers of disease (Zivadinov et al., 2009). These studies support the idea that HLA genes may influence the risk of multiple sclerosis in part through the immune control of EBV infection. Notably, remote infection with herpes simplex virus 1 was associated with a decreased risk of multiple sclerosis in DRB1*15-positive children, while the reverse was observed in those who were DRB1*15-negative (Waubant et al., 2011). Active replication of human herpesvirus-6 in the serum of patients with multiple sclerosis was associated with a polymorphism of the MHC2TA gene, which encodes a transcription factor involved in expression of MHC class II genes, including HLA DRB1*15 (Martinez et al., 2007).

The interplay between multiple infections is likely to contribute to multiple sclerosis risk and disease activity. Although prior infection with herpes simplex virus 1 was not an independent risk factor in a pediatric multiple sclerosis cohort, children seropositive for both herpes simplex virus and EBV were more likely to have multiple sclerosis as compared with children seropositive only for EBV (Banwell et al., 2007). Recent recognition of the vast numbers of commensal organisms that reside within an individual, termed the human microbiome, suggests that the manner in which microbes interact with each other and with the human genome to influence risk of multiple sclerosis and other autoimmune diseases is likely to be extremely complex (Ochoa-Reparaz et al., 2011).

**CONCLUSIONS**

The role of infections in multiple sclerosis remains a riddle. Infectious agents, particularly viruses, are the conspicuous candidates for the environmental factors in multiple sclerosis, but conclusive data are missing. Miscellaneous “virus-like” illnesses often precipitate attacks, but this may have little relevance to the more important issue of causation. Viruses can during a transient infection initiate an autoimmune disease, as seen with epitope spreading in animal experiments. Viral infection of nonneural tissues can set up demyelination by molecular mimicry or immune deregulation. Viruses...
that activate coincident with exacerbations of disease may be important or nonspecific. Virus, though causal, may not be recoverable at the time of disease, as in acute disseminated encephalomyelitis. Studies have not provided the desired answers but have defined the complexity of the questions. Finally, it may be that the childhood exposure is not to an infectious agent at all, but to some other factor that leads to both demyelinating disease and abnormal production of viral antibodies.

The delineation of different pathologic changes in acute multiple sclerosis lesions (Lucchinetti et al., 2000) raises the question of multiple mechanisms of pathogenesis in multiple sclerosis and consequently multiple causes. Historically a syndrome (signs and symptoms “that run together”) was assumed to have a common cause, but advances in both genetics and infectious diseases repeatedly provide contrary evidence. In genetics one phenotype often proves to have many genotypes, and single genotypes can be expressed as different phenotypes. In virology the neurologic syndrome of “aéseptic meningitis” has proved to be caused by over 100 different infectious agents, and conversely single agents such as HIV, varicella-zoster virus and Treponema pallidum can cause a spectrum of clinically and pathologically distinct diseases. Gilden (2005) and Lipton et al. (2007) in recent reviews support the idea of a “single multiple sclerosis virus”; but from a different vantage point one could consider some cases of tropical spastic paraplegia and Lyme encephalopathy with white-matter lesions dispersed in time and space. Before the discovery of HTLV-1 virus or Borrelia burgdorferi spirochete, these patients’ diseases fulfilled Schumacher’s criteria for multiple sclerosis. With present knowledge do we now regard these as disorders where, in our ignorance, we erred in diagnosis, or should we consider these as a small portion of that multiple sclerosis syndrome for which we now know the cause?

Finally, whether as a fundamental cause, as a trigger of attacks, or simply as an activation marker of activity, viruses appear related to multiple sclerosis. To maintain perspective we must recognize that the great majority of microbial agents in the world still defy current cultivation methods, but new technologies are being developed to identify them at a rapid pace (Relman, 2011). Within that panoply of potential human pathogens may lie the agent or agents responsible for multiple sclerosis.

REFERENCES

Adams JM, Imagawa DT (1962). Measles antibodies in multiple sclerosis. Proc Soc Exp Biol Med 111: 562–566.

Alonso A, Hernan MA (2008). Temporal trends in the incidence of multiple sclerosis. Neurology 71: 129–135.

Alter M, Kurtzke JF (1968). The Epidemiology of Multiple Sclerosis. Springfield, IL, Thomas.

Alvarez-Lafuente R, De Las Heras V et al. (2004). Arch Neurol 61: 1523–1527.

Anderson O, Lygnr P-E, Bergstrom T et al. (1993). Viral infections trigger multiple sclerosis relapses: a prospective soroepidemiological study. J Neurol 240: 417–422.

Andrews JM, Andrews RL (1973). The significance of dense core particles in subacute demyelinating disease in an adult. Lab Invest 28: 236–243.

Antony JM, Van Marle G, Opie W et al. (2004). Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci 7: 1088–1095.

Antony JM, Deslauriers AM, Bhat RK et al. (2011). Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants? Biochim Biophys Acta 1812: 162–176.

Ascherio A, Munch M (2000). Epstein–Barr virus and multiple sclerosis. Epidemiology 11: 220–224.

Axthelm MK, Koralnik IJ, Dang X et al. (2004). Meningoencephalitis and demyelination are pathologic manifestations of primary polyomavirus infection in immunosuppressed rhesus monkeys. J Neuropathol Exp Neurol 63: 750–758.

Bachmann S, Kesselring J (1998). Multiple sclerosis and infectious childhood diseases. Epidemiology 11: 220–224.

Bager P, Nielsen NM, Bihrmann K et al. (2004). Childhood infections and the risk of multiple sclerosis. Brain 127: 2491–2497.

Bagos PG, Nikolopoulos G, Ioannidis A (2006). Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis. Mult Scler 12: 397–411.

Bailey OT, Pappenheimer AM, Cheever FS et al. (1949). A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. II. Pathology. J Exp Med 90: 195–212.

Banwell B, Krupp L, Kennedy J et al. (2007). Clinical features and viral serologies in children with multiple sclerosis; a multinational observational study. Lancet Neurol 6: 773–781.

Beebe GW, Kurtzke JF, Kurland LT et al. (1967). Studies on the natural history of multiple sclerosis. III. Epidemiologic analysis of the Army experience in World War II. Neurology 17: 1–17.

Bender SI, Weiss SR (2010). Pathogenesis of murine coronavirus in the central nervous system. J Neuroimmune Pharmacol 5: 336–354.

Bequignon R (1956). De l’étiologie de la sclérose en plaques. C R Seances Acad Sci III 242: 1380–1382.

Bergstrom T, Andersen O, Vahle A (1989). Isolation of herpes simplex virus type 1 during first attack of multiple sclerosis. Ann Neurol 26: 283–285.

Boucher A, Desforges M, Duquette P et al. (2007). Long-term coronavirus-myelin cross-reactive T-cell clones derived from multiple sclerosis patients. Clin Immunol 258–267.

Brahic M, Bureau JF, Bas ET (2005). The genetics of the persistent infection and demyelinating disease caused by Theiler’s virus. Annu Rev Microbiol 59: 279–298.
Bray PF, Bloomer LC, Salmon VC et al. (1983). Epstein–Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 40: 406–408.

Bray PF, Culp KW, Mcfarlin DE et al. (1992). Demyelinating disease after neurologically complicated Epstein–Barr virus infection. Neurology 42: 278–282.

Brown P, Gajdusek DC (1974). No mouse PMN leucocyte depression after inoculation with brain tissue from multiple sclerosis or spongiform encephalopathies. Nature (Lond) 247: 217–218.

Buljevac D, Flach HZ, Hop WC et al. (2002). Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125: 952–960.

Burks JS, Devald BL, Jankovski LD et al. (1980). Two coronaviruses isolated from central nervous system tissue of two multiple sclerosis patients. Science 209: 933–939.

Bychkova EN (1964). Viruses isolated from patients with encephalomyelitis and multiple sclerosis. I. Pathologic and antigenic properties. Vopr Virusol 9: 173–176.

Cabre P, Olindo S, Merle H et al. (2005). Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 128: 2899–2901.

Cammer W, Bloom BR, Norton WT et al. (1978). Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination. Proc Natl Acad Sci U S A 75: 1554–1558.

Carp RI, Licursi PC, Merz PA et al. (1972). Decreased percentage of polymorphonuclear neutrophils in mouse peripheral blood after inoculation with material from: multiple sclerosis patients. J Exp Med 136: 618–629.

Carp RC, Licursi PC, Merz PA (1977). Multiple sclerosis-associated agent. Lancet 2: 814.

Cermelli C, Berti R, Soldan SS et al. (2003). High frequency of human herpesvirus 6 DNA in multiple sclerosis plaques isolated by laser capture microdissection. J Infect Dis 187: 1377–1387.

Challoner PB, Smith KT, Parker JD et al. (1995). Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A 92: 7440–7444.

Cheever FS, Daniels JB, Pappenheimer et al. (1949). A murine virus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin. I. Isolation and biological properties of the virus. J Exp Med 90: 181–194.

Chevassut K (1930). The aetiology of disseminated sclerosis. Lancet 1: 552–560.

Christensen T (2005). Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol 15: 179–211.

Christensen KL, Holman RC, Hammet TA et al. (2010). Progressive multifocal leukoencephalopathy deaths in the USA, 1979–2005. Neuroepidemiology 35: 178–184.

Clements JE, Zink MC (1996). Molecular biology and pathogenesis of animal lentivirus infections. Clin Microbiol Rev 9: 100–117.

Clements JE, Pedersen FC, Narayan O et al. (1980). Genomic changes associated with antigenic variation of visna virus during persistent infection. Proc Natl Acad Sci U S A 77: 4454–4458.

Cook SD, Dowling PC (1977). A possible association between house pets and multiple sclerosis. Lancet 1: 980–982.

Cook SD, Dowling PC (1984). Distemper and multiple sclerosis in Sitka, Alaska. Ann Neurol 11: 192–194.

Cook SD, Dowling PC, Russell WC (1978). Multiple sclerosis and canine distemper. Lancet 1: 605–606.

Cork LC, Narayan O (1980). The pathogenesis of viral leukoencephalomyelitis-arthritis of goats. I. Persistent viral infection with progressive pathologic changes. Lab Invest 42: 596–602.

Correale J, Farez M (2007). Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 61: 97–108.

Cremer NE, Johnson KP, Fein G et al. (1980). Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and cerebral spinal fluid antibodies by standard serologic methods. Arch Neurol 37: 610–615.

Daniels JB, Pappenheimer AM, Richardson R (1952). Observations on encephalomyelitis of mice (DA strain). J Exp Med 96: 517–530.

De Jager PL, Simon KC, Munger KL et al. (2008). Integrating risk factors: HLA-DRB1*1501 and Epstein–Barr virus in multiple sclerosis. Neurology 70: 1113–1118.

Dean G (1970). The multiple sclerosis problem. Sci Am 233: 40–46.

Dean G, Kurtzke JF (1971). On the risk of multiple sclerosis according to age at immigration to South Africa. Br Med J 3: 725–729.

Dick GW, Mckeown F, Wilson DC (1958). Virus of acute encephalomyelitis of man and multiple sclerosis. Br Med J 1: 7–9.

Dolei A (2005). MSRV/HERV-W/syncytin and its linkage to multiple sclerosis: the usability and the hazard of a human endogenous retrovirus. J Neurovirol 11: 232–235.

Dolei A, Serra C, Mameli G et al. (2002). Multiple sclerosis associated retrovirus (MSRV) in Sardinian MS patients. Neurology 58: 471–473.

Dyson F (1982). Unfashionable pursuits. In: H Hanle (Ed.), Alexander von Humboldt Foundation Bi-National Colloquium. Bonn, Bad Godesberg.

Esolen LH, Takahashi K, Johnson RT et al. (1995). Brain endothelial cell infection in children with acute fatal measles. J Clin Invest 96: 2478–2481.

Fainardi E, Castellazzi M, Tamborino C et al. (2009). Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms. J Neurovirol 15: 425–433.

Farrell RA, Antony D, Wall GR et al. (2009). Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73: 32–38.

Ferrante P, Omodeo-Zorini E, Cladarelli-Stefano R et al. (1998). Detection of JC virus DNA in cerebrospinal fluid from multiple sclerosis patients. Mult Scler 4: 49–54.

Field EJ, Cowshall S, Narang HK et al. (1972). Viruses in multiple sclerosis? Lancet 2: 280–281.

Fleming J, Fabry Z (2007). The hygiene hypothesis and multiple sclerosis. Ann Neurol 61: 85–89.
Kim TS, Perlman S (2005). Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with neurotropic coronavirus. Am J Pathol 166: 801–809.

Kinnunen E, Valle M, Pirirainen L et al. (1990). Viral antibodies in multiple sclerosis. A nationwide co-twin study. Arch Neurol 47: 743–746.

Kirk J (1979). Pseudo-viral hollow-cored vesicles in multiple sclerosis brain. Acta Neuropathol 48: 63–66.

Knox KK, Brewer JH, Henry JM et al. (2000). Human herpesvirus 6 and multiple sclerosis. Systemic active infections in patients with early disease. Clin Infect Dis 31: 894–903.

Koprowski H, De Freitas EC, Harper ME et al. (1985). Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature 318: 154–160.

Kuhn P, Steiner G (1917). Über die Ursache der multiplen Sklerose. Klin Med (Moscow) 13: 1007–1009.

Kurtzke JF (1983). Some epidemiological trends in multiple sclerosis. Trends Neurosci. 6: 75–80.

Kurtzke JF (2000). Multiple sclerosis in time and space – geographic clues to cause. J Neurol 257: suppl 2: S134–S140.

Kurtzke JF (2005). Epidemiology and etiology of multiple sclerosis. Phys Med Rehabil Clin N Am 16: 327–349.

Kurtzke JF, Martin A, Myerson RM et al. (1962). Microbiology in multiple sclerosis – evaluation of Ichelson’s organization. Neurology 12: 915–922.

Kurtzke JF, Gudmundsson KR, Bergmann S (1982). Multiple sclerosis Iceland. I. Evidence of a post-war epidemic. Neurology 32: 143–150.

Kurtzke JF, Hyllested K, Heltberg A (1995). Multiple sclerosis and Epstein–Barr virus. JAMA 274: 1533–1536.

Lampert F, Lampert P (1975). Multiple sclerosis. Arch Neurol 32: 425–427.

Lampert P, Sims JK, Kniazeff AJ (1973). Mechanism of demyelination in JHM virus encephalomyelitis – electron microscopic studies. Acta Neuropatohl 24: 76–85.

Lang HLE, Jacobsen H, Ikemizu S et al. (2002). A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 3: 940–943.

Le Gac P (1960). Le traitement de la sclerose en plaques d’origine rickettsienne et neorickettsienne. J Med Bord 137: 158–169.

Leibowitz U, Antonovsky A, Medalie JM et al. (1966). Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation. J Neurol Neurosurg Psychiatry 29: 60–68.

Levin MC, Lee SM, Kalume F et al. (2002). Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 8: 509–513.

Levin LI, Munger KL, Rubertone MV et al. (2003). Multiple sclerosis and Epstein–Barr virus. JAMA 289: 1533–1536.

Lipton HL (1975). Theiler’s virus infection in mice – an unusual biphasic disease process leading to demyelination. Infect Immun 1: 1147–1155.

Lipton HL, Dal Canto MC (1976). Theiler’s virus-induced demyelination – prevention by immuno-suppression. Science 192: 62–64.

Lipton HL, Kumar AS, Trottier M (2005). Theiler’s virus persistence in the central nervous system of mice is associated with continuous viral replication and difference in outcome of infections of infiltrating macrophages versus oligodendrocytes. Virus Res 111: 214–223.

Lipton HL, Liu Z, Herzler S et al. (2007). A specific viral cause of multiple sclerosis: one virus, one disease. Ann Neurol 61: 514–523.

Lucas RM, Ponsonby AL, Dear K et al. (2011). Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology 77: 371–379.

Lucchinetti C, Bruck W, Parisi J et al. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707–717.

Margulis MS, Soloviev VD, Schubladze AK (1946). Aetiology and pathogenesis of acute sporadic disseminated encephalomyelitis and multiple sclerosis. J Neurol Neurosurg Psychiatry 9: 62–74.

Marie P (1884). Scle´rose en plaques et maladies infectieuses. Progr Med 12: 287–289.

Markovic-Plese S, Hemmer B, Zhao Y et al. (2005). High level of cross-reactivity in influenza virus hemagglutinin-specific CD4 + T cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 169: 31–38.

Martinez A, Alvarez-Lafente R, Mas A et al. (2007). Environment–gene interaction in multiple sclerosis: human herpesvirus 6 and MHC2TA. Hum Immunol 68: 685–689.

Matyn CN, Cruddas M, Compston DAS (1993). Symptomatic Epstein–Barr virus infection and multiple sclerosis. J Neurol Neurosurg Psychiatry 56: 167–168.

McCullough B, Krakowska S, Koestner A (1974). Experimental canine distemper virus-induced demyelination. Lab Invest 31: 216–222.

McElroy JP, Oksenberg JR (2011). Multiple sclerosis genetics 2010. Neurol Clin 29: 219–231.

Melnick JL (1982). Has the virus of multiple sclerosis been isolated? Yale J Biol Med 55: 251–257.

Melnick JL, Seidel E, Inoue YK et al. (1982). Isolation of virus from spinal fluid of three patients with multiple sclerosis and one with atomyotropic lateral sclerosis. Lancet 1: 830–833.

Mitchell DN, Porterfield JS, Micheletti R et al. (1978). Isolation of an infectious agent from bone-marrows of patients with multiple sclerosis. Lancet 2: 387–390.

Mitchell DN, Goswami KKA, Taylor P et al. (1979). Failure to isolate a transmissible agent from the bone-marrow of patients with multiple sclerosis. Lancet 2: 415–416.

Moench TR, Griffin DE, Obriecht CR et al. (1988). Acute measles in patients with and without neurological involvement: distribution of measles antigen and RNA. J Infect Dis 158: 433–442.

Montomoli C, Allemani C, Solinas G et al. (2002). An ecologic study of geographic variation in multiple sclerosis risk in central Sardinia, Italy. Neuroepidemiology 21: 187–193.
Munger KL, Delorenze GN, Levin LI et al. (2004). A prospective study of *Chlamydia pneumoniae* infection and risk of MS in two US cohorts. Neurology 62: 1799–1803.

Murray JT (2005). Multiple Sclerosis: The History of a Disease. Demos, New York.

Narayan O, Cork LC (1985). Lentivirus diseases of sheep and goats – chronic pneumonia, leukoencephalomyelitis and arthritis. Rev Infect Dis 7: 89–98.

Narayan O, Griffin DE, Clements JE (1978). Virus mutation during “slow infection” temporal development and characterization of mutants of visna virus recovered from sheep. J Gen Virol 41: 343–352.

Narayan O, Sheffer D, Clements JE et al. (1983). Activation of caprine arthritis-encephalitis virus expression during maturation of monocytes to macrophages. Infect Immun 4: 67–73.

Nath A, Wolinsky JS (1990). Antibody response to rubella virus structural proteins in multiple sclerosis. Ann Neurol 27: 533–536.

Nathanson N, Georgsson G, Palsson PA et al. (1985). Visna, the prototype lentivirus infection. Rev Infect Dis 7: 75–82.

Noorbakhsh F, Johnson RT, Emery D et al. (2008). Acute disseminated encephalomyelitis: clinical and pathogenesis features. Neurology Clin 26: 759–780.

Norby E (1978). Viral antibodies in multiple sclerosis. Prog Med Virol 24: 1–39.

Norby E, Link H, Olsson JE et al. (1974). Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. Infect Immun 10: 688–694.

Ochoa-Repaz J, Mielcarz DW, Begum-Haque S et al. (2011). Gut, bugs, and brain: role of commensal bacteria in the control of central nervous system disease. Ann Neurol 69: 240–247.

Opsahl ML, Kennedy PG (2005). Early and late HIV-1 gene transcripts in multiple sclerosis lesions and normal appearing white matter. Brain 128: 516–527.

Ordómez G, Pineda B, García-Navarrete R et al. (2004). Brief presence of varicella-zoster viral DNA in mononuclear cells during relapses of multiple sclerosis. Arch Neurol 61: 529–532.

Padgett BL, Walker DL, Zurhein GM et al. (1976). JC papovavirus in progressive multifocal leukoencephalopathy. J Infect Dis 133: 686–690.

Palsson PA, Pattison IH, Field EJ (1965). Transmission experiments with multiple sclerosis. In: DC Gajdusek, CJ Gibbs Jr, M Aplers (Eds.), Slow, Latent and temperate Virus Infections. U.S. Government Printing Office, Washington, DC, pp. 49–54.

Pedneault L, Katz BZ, Miller G (1992). Detection of Epstein–Barr virus in the brain by polymerase chain reaction. Ann Neurol 32: 184–192.

Perron H, Seigneurin JM (1999). Human retroviral sequences associated with extracellular particles in autoimmune disease Epiphenomenon or possible role in actiopathogenesis? Microbes Infect 1: 309–322.

Perron H, Geny C, Laurent A et al. (1989). Leptomeningeal cell line from multiple sclerosis with reverse transcriptase activity and viral particles. Res Virol 140: 551–561.

Perron H, Lalande BZ, Gratacap B et al. (1991). Isolation of retrovirus from patients with multiple sclerosis. Lancet 337: 862–863.

Pietropaolo V, Fioriti D, Mischitelli M et al. (2005). Detection of human herpesviruses and polyomaviruses DNA in a group of patients with relapsing-remitting multiple sclerosis. New Microbiol 28: 199–203.

Poh D, Krone B, Rostas K et al. (2006). High seroprevalence of Epstein–Barr virus in children with multiple sclerosis. Neurology 67: 2063–2065.

Poskanzer DC, Schapira K, Miller H (1963). Multiple sclerosis and poliomyelitis. Lancet 2: 917–921.

Purves-Stewart J (1930). A specific vaccine treatment in disseminated sclerosis. Lancet 1: 560–564.

Purves-Stewart J (1931). Disseminated sclerosis – experimental vaccine treatment. Lancet 1: 440–441.

Raine CS (1976). On the development of central nervous system lesions in natural canine distemper encephalomyelitis. J Neurol Sci 30: 13–28.

Rand KH, Houck H, Denslow ND et al. (2000). Epstein–Barr virus nuclear antigen-1 (EBNA-1) associated oligoclonal bands in patients with multiple sclerosis. J Neurol Sci 173: 32–39.

Relman DA (2011). Microbial genomics and infectious disease. N Engl J Med 365: 347–357.

Ristori G, Cannoni S, Stazi MA et al. (2006). Multiple sclerosis in twins from continental Italy and Sardinia; a nationwide study. Ann Neurol 59: 27–34.

Rivers TM, Schwentker FF (1935). Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med 6: 689–702.

Ross RT, Cheang M (1995). Geographic similarities between varicella and multiple sclerosis: an hypothesis on the environmental factor of multiple sclerosis. J Clin Epidemiol 48: 731–737.

Ryschkewitsch C, Jenson P, Hou J et al. (2004). Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JC and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 121: 217–221.

Sadovnick AD (2006). The genetics and genetic epidemiology of multiple sclerosis: the “hard facts”. Adv Neurol 98: 17–25.

Salmi A, Reunanen M, Ionen J et al. (1983). Intrathecal antibody synthesis to virus antigens in multiple sclerosis. Clin Exp Immunol 52: 241–249.

Sanders VJ, Waddell AE, Felisan SL et al. (1996). Herpes simplex virus in postmortem brain tissue. Arch Neurol 53: 125–133.

Santiago O, Gutierrez J, Sorlozano A et al. (2010). Relation between Epstein–Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis 29: 857–866.

Schaltenbrand C (1943). Die Multiple Sklerose des Menschen. Thieme, Leipzig.

Serafini B, Severa M, Columba-Cabezas S et al. (2010). Epstein–Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications
for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol 69: 677–693.

Shaw CM, Alvord EC Jr (1987). Multiple sclerosis beginning in infancy. J Child Neurol 2: 252–256.

Sigurðsson B, Palsson PA (1958). Visna of sheep – a slow, demyelinating infection. Br J Exp Pathol 39: 519–528.

Sips GJ, Chesik D, Glazenburg L et al. (2007). Involvement of morbilliviruses in the pathogenesis of demyelinating disease. Rev Med Virol 17: 223–244.

Soldan SS, Fogell-Hahn A, Brennan MB et al. (2001). Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Ann Neurol 50: 486–493.

Sotgiu S, Mameli G, Serra C et al. (2010). Multiple sclerosis-associated retrovirus and progressive disability of multiple sclerosis. Mult Scler 16: 1248–1251.

Sriram S, Stratton CW, Yao S et al. (1999). Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 46: 6–14.

Steiner G (1952). Acute plaques in multiple sclerosis, their pathogenetic significance and role of spongioasias as etiological factor. J Neuropathol Exp Neurol 11: 343–372.

Stevens JG, Bastone VB, Ellison GW et al. (1980). No measles virus genetic information detected in multiple sclerosis-derived brains. Ann Neurol 8: 625–637.

Stohlman SA, Hinton DR (2001). Viral induced demyelination. Brain Pathol 11: 92–106.

Subramaniam S, Steiner I (2005). Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 58: 939–945.

Sullivan CB, Vischer BR, Detels R (1984). Multiple sclerosis and age at exposure to childhood disease and animals – cases and their friends. Neurology 34: 1144–1148.

Sundström P, Juto P, Wadell G et al. (1972). Fusion of cultured multiple sclerosis brain cells with indicator cells – presence of nucleocapsids and virions and isolation of parainfluenza-type virus. Lancet 2: 1–5.

Theiler M (1934). Spontaneous encephalomyelitis of mice – a new virus disease. Science 80: 122.

Tompkins SM, Fuller KG, Miller SD (2002). Theiler’s virus-mediated autoimmunity: local presentation of CNS antigens and epitope spreading. Ann N Y Acad Sci 958: 26–38.

Tomsone V, Logina I, Millers A et al. (2001). Activation of human herpesvirus 6 and human herpesvirus 7 with demyelinating diseases of the nervous system. J Neurovirol 7: 564–569.

Torkildsen O, Nyland H, Myrmel H et al. (2008). Epstein–Barr virus reactivation and multiple sclerosis. Eur J Neurol 15: 106–108.

Tomatore C, Berger JR, Houff SA et al. (1992). Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 31: 454–462.

Tsunoda I, Fujinami RS (2010). Neuropathogenesis of Theiler’s murine encephalomyelitis virus infection, an animal model for multiple sclerosis. J Neuroimmune Pharmacol 5: 355–369.

Tzartos JS, Khan G, Vossenkamper A et al. (2012). Association of innate immune activation with latent Epstein–Barr virus in active MS lesions. Neurology 78: 15–23.

Vagabov RMA, Skortsos TM, Golman YP et al. (1982). Isolation of the tick-borne encephalitis virus from patient with multiple sclerosis. Acta Virol 20: 403.

Vandevelde M, Zurbriggen A (2005). Demyelination in canine distemper virus infections: a review. Acta Neuropathol 109: 56–68.

Virtanen JO, Jacobson S (2012). Viruses and multiple sclerosis. CNS Neurol Drug Targets 11: 528–544.

Voisset C, Blanche R, Perron H et al. (1999). Phylogeny of a novel family of human endogenous retrovirus sequences HERV-Win humans and other primates. AIDS Res Hum Retroviruses 5: 1529–1533.

Wallin MT, Page WF, Kurtzke JF (2004). Multiple sclerosis in US veterans of Vietnam era and later military service: race, sex, and geography. Ann Neurol 55: 65–71.

Wallin MT, Heltberg A, Kurtzke JF (2010). Multiple sclerosis in the Faroe Islands 8 Notifiable diseases. Acta Neurol Scand 122: 102–109.

Wandinger K, Jabs W, Siekhaus A et al. (2000). Association between clinical disease activity and Epstein–Barr virus reactivation in MS. Neurology 55: 178–184.

Waubant E, Mowry EM, Krupp L et al. (2011). Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76: 1989–1995.

Weiner LP (1973). The pathogenesis of demyelination induced by mouse hepatitis virus (JHM virus). Arch Neurol 28: 298–303.

Weiss SR (1983). Coronaviruses SD and SK share extensive nucleotide homology with murine coronaviruses MHV-A59, more than that shared between human and murine coronaviruses. Virology 126: 669–677.

Wilborn F, Schmidt CA, Brinkmann V et al. (1994). A potential role for human herpesvirus type 6 in nervous system disease. J Immunol 49: 213–214.

Willer CJ, Dyment DA, Risch NJ et al. (2003). Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 100: 12877–12882.

Wroblewska Z, Gilden D, Delvin M et al. (1979). Cytomegalovirus isolation from a chimpanzee with acute demyelinating disease after inoculation of multiple sclerosis brain cells. Infect Immun 25: 1008–1015.
Wuthrich C, Cheng YM, Joseph JT et al. (2009). Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 68: 15–25.

Wyss-Fluehmann G, Zurbriggen A, Vandevelde M et al. (2010). Canine distemper virus persistence in demyelinating encephalitis by swift intracellular cell-to-cell spread in astrocytes is controlled by the viral attachment protein. Acta Neuropathol 119: 617–630.

Yao SY, Stratton CW, Mitchell WN et al. (2001). CSF oligoclonal bands in MS contain antibodies against Chlamydia antigens. Neurology 56: 1168–1176.

Zivadinov R, Weinstock-Guttman B, Zorzon M et al. (2009). Gene–environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 209: 123–130.

Zurhein GM (1969). Association of papovaviruses with a human demyelinating disease (progressive multifocal leukoencephalopathy). Prog Med Virol 11: 185–247.